TCP
ALXN

Tourbillon Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Tourbillon Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-375,000
Closed -$41.8M – 99
2018
Q1 		$41.8M Sell
375,000
-275,000
-42% -$32.9M 1.66% 21
2017
Q4 		$77.7M Buy
+650,000
New +$79.2M 2.88% 10
2017
Q1 		– Sell
-252,000
Closed -$30.8M – 82
2016
Q4 		$30.8M Buy
+252,000
New +$30.8M 0.59% 43

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tourbillon Capital Partners's ALXN Position: Q3 2018 in Review

Tourbillon Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 353,106 shares — an estimated $43.8M sold.

Tourbillon Capital Partners first reported a position in ALXN in Q2 2016 and held it in 9 quarters. The position peaked at $221M in Q3 2017. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Tourbillon Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Tourbillon Capital Partners sold 353,106 Alexion Pharmaceuticals shares in Q3 2018, an estimated $43.8M.
  • Tourbillon Capital Partners first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 9 quarters.
  • Tourbillon Capital Partners's Alexion Pharmaceuticals position peaked at $221M in Q3 2017.
  • 585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Tourbillon Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.